Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kailera TherapeuticsKLRA -0.54%12 Debt-to-Equity is 0.01 as of Jun. 2026. GuruFocus rates KLRA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 966 Biotechnology companies, Kailera Therapeutics ranks better than 99.9% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Kailera Therapeutics's Debt-to-Equity or its related term are showing as below:
KLRA'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.03 Med: -0.01 Max: 0.01
Current: 0.01
During the past 2 years, the highest Debt-to-Equity Ratio of Kailera Therapeutics was 0.01. The lowest was -0.03. And the median was -0.01.
KLRA's Debt-to-Equity is ranked better than 99.9% of 966
companies
in the Biotechnology industry
Industry Median: 0.15
vs KLRA: 0.01
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Kailera Therapeutics Debt-to-Equity Related Terms
Kailera Therapeutics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Kailera Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kailera Therapeutics Debt-to-Equity Chart
Kailera Therapeutics Annual Data
Trend
Dec24
Dec25
Debt-to-Equity
0.00
0.02
Kailera Therapeutics Quarterly Data
Jun25
Mar26
Jun26
Debt-to-Equity
-
0.02
0.01
KLRA vs VCEL, ADMA, COAG: Debt-to-Equity Comparison
For the Biotechnology subindustry, Kailera Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kailera Therapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kailera Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Kailera Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kailera Therapeutics (KLRA) has a Debt-to-Equity of 0.01 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Kailera Therapeutics and its competitors. According to the industry distribution chart, Kailera Therapeutics ranks #1 out of 966 companies in the Biotechnology industry, placing it in the top 0.099999999999994%.
Is Kailera Therapeutics' Debt-to-Equity too high?
Kailera Therapeutics' current Debt-to-Equity is 0.01. The Biotechnology industry median Debt-to-Equity is 0.15. Kailera Therapeutics' value of 0.01 is 93.3% below this industry median. Based on the distribution chart, Kailera Therapeutics ranks #1 out of 966 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Kailera Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Kailera Therapeutics' Debt-to-Equity compare to VCEL and ADMA?
According to the Biotechnology industry distribution chart, Kailera Therapeutics ranks #1 out of 966 companies for Debt-to-Equity. This places Kailera Therapeutics in the top 0% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.15. Kailera Therapeutics' value of 0.01 is 93.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.15, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kailera Therapeutics's current Debt-to-Equity of 0.01 is 93.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Kailera Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kailera Therapeutics's current Debt-to-Equity is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kailera Therapeutics stock overvalued right now?
Kailera Therapeutics (KLRA) has a current Debt-to-Equity of 0.01. The current Debt-to-Equity is 0.01 and 93.3% below the Biotechnology industry median of 0.15. Kailera Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Kailera Therapeutics (KLRA), the current Debt-to-Equity is 0.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
12GF Score
Get the complete analysis for KLRA
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KLRA has been successfully added to your 
